Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
Rapoport BL, Aapro M, Paesmans M, van Eeden R, Smit T, Krendyukov A, Klastersky J. Rapoport BL, et al. Among authors: krendyukov a. BMC Cancer. 2018 Sep 24;18(1):917. doi: 10.1186/s12885-018-4838-z. BMC Cancer. 2018. PMID: 30249215 Free PMC article.
Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M, Bokemeyer C, Ludwig H, Gascón P, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, MacDonald K, Abraham I. Aapro M, et al. Among authors: krendyukov a. J Geriatr Oncol. 2017 Mar;8(2):86-95. doi: 10.1016/j.jgo.2016.09.006. Epub 2016 Nov 6. J Geriatr Oncol. 2017. PMID: 27829539 Free article.
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K. Bokemeyer C, et al. Among authors: krendyukov a. Support Care Cancer. 2017 Jun;25(6):1819-1828. doi: 10.1007/s00520-017-3572-4. Epub 2017 Jan 22. Support Care Cancer. 2017. PMID: 28111718 Free PMC article.
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K, Gascon P, Krendyukov A, Gattu S, Li Y, Harbeck N. Blackwell K, et al. Among authors: krendyukov a. Ann Oncol. 2018 Jan 1;29(1):244-249. doi: 10.1093/annonc/mdx638. Ann Oncol. 2018. PMID: 29091995 Free article. Clinical Trial.
Development and 10-year history of a biosimilar: the example of Binocrit®.
Aapro M, Krendyukov A, Höbel N, Seidl A, Gascón P. Aapro M, et al. Among authors: krendyukov a. Ther Adv Med Oncol. 2018 Apr 17;10:1758835918768419. doi: 10.1177/1758835918768419. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29707043 Free PMC article. Review.
44 results